Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Marqeta Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Marqeta Inc trades at $18.1 (market cap $1.93B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 4.4× Marqeta Inc's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Marqeta Inc for 44 Days on average.
| HNGE | MQ | |
|---|---|---|
Market Cap | $8.48B | $1.93B |
Volume | 879,799 | 915,027 |
Sector | Health | Technology |
52-Week High | $105.14 | $20.32 |
52-Week Low | $31.17 | $15.04 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $8.10B | $1.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Marqeta (MQ) trades at $18.18, down 0.6% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 showing 17% net revenue growth and GAAP profitability. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. Cash flow turned positive in 2025 at $86.42M, a significant improvement from prior years' losses.
Outlook is mixed: strong revenue growth and product initiatives support upside, but high P/E of 206.22 and thin net margin of 1.53% pose valuation risks. Analyst consensus is cautious with a $11.38 price target, well below current levels. Key risks include contract renewals in Q3 2026 and competitive pressures in fintech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
